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INTRODUCTION
1Internal Medicine Resident, 2Nephrology Fellow, Lehigh Valley Health Network, Allentown, Pennsylvania
Nivolumab is a checkpoint immunotherapy that has become a primary treatment modality for patients 
with advanced melanoma and non-small cell lung carcinoma (NSCLC). New immunotherapy treatments 
can result in unique adverse events due to increased inflammation in any organ in the body. 
DISCUSSION
Immune related inflammation and metastatic disease in the pancreas 
in combination with nivolumab immunotherapy likely caused 
pancreatic insufficiency resulting in new-onset diabetes. The cause of 
this phenomenon is presumed to be due to inappropriate activation of 
T-cells resulting in damage to normal tissues. Few case reports have 
highlighted adverse effects of nivolumab causing immune-related 
pancreatitis or rapid onset insulin-dependent diabetes. The case report 
herein demonstrates both immune-related pancreatitis and new- 
onset insulin-dependent diabetes developing after only one treatment 
with nivolumab. All medical professionals should be able to recognize 
immune-related adverse events due to immunotherapy medications to 
appropriately diagnose patients. 
CASE REPORT
A 64-year-old Vietnamese male with a history of stage IIIA NSCLC 
was treated with Taxol, Carboplatin and radiation therapy with 
good response. Two years later, computed tomography (CT) 
scan demonstrated metastases to the liver and pancreas. The 
patient began treatment with nivolumab. Two weeks after the 
initial nivolumab treatment, the patient complained of significant 
abdominal pain. Repeat CT imaging showed disease progression 
in the liver and pancreas with mild inflammation of the pancreatic 
tail. Hospital admission blood work showed lipase of 4479 U/L 
and CRP of 179 mg/L, which is consistent with immune related 
pancreatitis. He was treated with methylprednisolone 1.2mg/kg/
day with improvement in pain and lipase levels. Ten days after 
starting steroid treatment, outpatient lab work revealed significant 
lab derangements including blood glucose 649 mg/dL, sodium 
126 mmol/L, elevated creatinine of 1.35 mg/dL and an anion gap 
of 14. The patient had no known history of diabetes. The patient 
did complain of polyuria and polydipsia for the previous 10 days. 
Hemoglobin A1C resulted at 11%. Glutamic acid decarboxylase 
antibody was negative, islet cell antibody was negative, zinc 
transporter 8 antibody was negative, and C Peptide level was low 
at 0.3 ng/mL. The patient was started on insulin as treatment for 
his elevated blood sugars and low insulin levels. 
Image 3: CT Abdomen/Pelvis. Pancreatic mass noted.
Image 4: CT Abdomen/Pelvis. Pancreatic inflammation 
noted.
Image 1: T cells inactivated by cancer cells through PD-L1/PD-
L2 receptor
Image 2: Nivolumab utilized to maintain T cell activation 
against cancer cells, and some healthy cells
Image 5: Immune related adverse reactions caused by Nivolumab.
